ICJR Interviews: The Use of TXA in Hip Fracture Patients
The benefits of tranexamic acid (TXA) in reducing blood loss and transfusion rates in patients undergoing elective total hip arthroplasty are well documented.
Would the same benefits extend to patient undergoing non-elective total hip arthroplasty – in other words, patients with femoral neck fractures?
That was the question Chad Watts, MD, and his colleagues from Mayo Clinic, Rochester, Minnesota, sought to answer with their study, “Tranexamic Acid Safely Reduced Blood Loss: Randomized Clinical Trial of 138 Femoral Neck Fractures” (Paper 385), which was recently presented at the 2016 Annual Meeting of the American Academy of Orthopaedic Surgeons in Orlando.
This was a prospective, double-blinded, randomized controlled trial in which they randomized 138 patients to receive either intravenous TXA or a saline placebo infusion.
Dr. Watts and his colleagues found that TXA use is safe in this older, generally frail patient population, with no differences between groups in adverse events, mortality, or readmissions.
TXA is also effective in these patients: Blood loss was significantly lower in the TXA group. However, although there was a trend toward reduction in transfusion rates, the difference was not significant.
Click the image above to here Dr. Watts describe the rationale for the study and what the findings mean.
Producer: Susan Doan-Johnson; Director: Michael Bugera; Post Production: Charles J. Maynard